-
2
-
-
41849123889
-
Establishing the role of cytokine therapy in advanced renal cell carcinoma
-
Gore ME, De Mulder P. Establishing the role of cytokine therapy in advanced renal cell carcinoma. BJU Int 2008; 101: 1063-70.
-
(2008)
BJU Int
, vol.101
, pp. 1063-1070
-
-
Gore, M.E.1
De Mulder, P.2
-
4
-
-
33748569461
-
Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
-
Vogl UM, Zehetgruber H, Dominkus M et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 2006; 95: 691-8.
-
(2006)
Br J Cancer
, vol.95
, pp. 691-698
-
-
Vogl, U.M.1
Zehetgruber, H.2
Dominkus, M.3
-
5
-
-
4644335916
-
Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma
-
Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004; 10: 6342S-6S.
-
(2004)
Clin Cancer Res
, vol.10
-
-
Atkins, M.B.1
Regan, M.2
McDermott, D.3
-
6
-
-
18944385751
-
Immunotherapy for advanced renal cell cancer
-
Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 1: CD001425.
-
(2005)
Cochrane Database Syst Rev
, vol.1
-
-
Coppin, C.1
Porzsolt, F.2
Awa, A.3
Kumpf, J.4
Coldman, A.5
Wilt, T.6
-
7
-
-
76749116183
-
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
-
Gore ME, Griffin CL, Hancock B et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010; 375: 641-8.
-
(2010)
Lancet
, vol.375
, pp. 641-648
-
-
Gore, M.E.1
Griffin, C.L.2
Hancock, B.3
-
8
-
-
0036138580
-
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
-
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96.
-
(2002)
J Clin Oncol
, vol.20
, pp. 289-296
-
-
Motzer, R.J.1
Bacik, J.2
Murphy, B.A.3
Russo, P.4
Mazumdar, M.5
-
9
-
-
0032471712
-
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response
-
Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228: 307-19.
-
(1998)
Ann Surg
, vol.228
, pp. 307-319
-
-
Rosenberg, S.A.1
Yang, J.C.2
White, D.E.3
Steinberg, S.M.4
-
10
-
-
33846200478
-
Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents
-
Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 2007; 99: 274-80.
-
(2007)
BJU Int
, vol.99
, pp. 274-280
-
-
Bellmunt, J.1
Montagut, C.2
Albiol, S.3
Carles, J.4
Maroto, P.5
Orsola, A.6
-
11
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
12
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
13
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
-
Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11.
-
(2007)
Lancet
, vol.370
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
-
14
-
-
56749161699
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
-
Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5422-5428
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
-
15
-
-
34248345563
-
The renin angiotensin system in the regulation of angiogenesis
-
Heffelfinger SC. The renin angiotensin system in the regulation of angiogenesis. Curr Pharm Des 2007; 13: 1215-29.
-
(2007)
Curr Pharm Des
, vol.13
, pp. 1215-1229
-
-
Heffelfinger, S.C.1
-
16
-
-
0026577981
-
High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study
-
Inhorn L, Williams SD, Nattam S, Stephens D. High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study. Am J Clin Oncol 1992; 15: 157-9.
-
(1992)
Am J Clin Oncol
, vol.15
, pp. 157-159
-
-
Inhorn, L.1
Williams, S.D.2
Nattam, S.3
Stephens, D.4
-
17
-
-
33644859805
-
Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review)
-
Lefranc F, Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review). Int J Oncol 2006; 28: 1021-30.
-
(2006)
Int J Oncol
, vol.28
, pp. 1021-1030
-
-
Lefranc, F.1
Yeaton, P.2
Brotchi, J.3
Kiss, R.4
-
18
-
-
0036681694
-
Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis
-
Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002; 62: 4176-9.
-
(2002)
Cancer Res
, vol.62
, pp. 4176-4179
-
-
Miyajima, A.1
Kosaka, T.2
Asano, T.3
Seta, K.4
Kawai, T.5
Hayakawa, M.6
-
19
-
-
31544455868
-
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
-
Rini BI, Weinberg V, Dunlap S et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006; 106: 566-75.
-
(2006)
Cancer
, vol.106
, pp. 566-575
-
-
Rini, B.I.1
Weinberg, V.2
Dunlap, S.3
-
20
-
-
70449333312
-
Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma
-
Shinohara N, Kumagai A, Kanagawa K et al. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jpn J Clin Oncol 2009; 39: 720-6.
-
(2009)
Jpn J Clin Oncol
, vol.39
, pp. 720-726
-
-
Shinohara, N.1
Kumagai, A.2
Kanagawa, K.3
-
21
-
-
37849053338
-
Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment
-
Uemura H, Ishiguro H, Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 2008; 15: 19-26.
-
(2008)
Int J Urol
, vol.15
, pp. 19-26
-
-
Uemura, H.1
Ishiguro, H.2
Kubota, Y.3
-
22
-
-
51349138395
-
Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: report of three cases
-
Tatokoro M, Fujii Y, Kawakami S et al. Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: report of three cases. Int J Urol 2008; 15: 848-50.
-
(2008)
Int J Urol
, vol.15
, pp. 848-850
-
-
Tatokoro, M.1
Fujii, Y.2
Kawakami, S.3
-
24
-
-
33745319059
-
Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis
-
Kinouchi T, Sakamoto J, Tsukamoto T et al. Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis. J Cancer Res Clin Oncol 2006; 132: 499-504.
-
(2006)
J Cancer Res Clin Oncol
, vol.132
, pp. 499-504
-
-
Kinouchi, T.1
Sakamoto, J.2
Tsukamoto, T.3
-
25
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
26
-
-
65949102289
-
Immunotherapy of metastatic renal cell carcinoma
-
McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009; 115: 2298-305.
-
(2009)
Cancer
, vol.115
, pp. 2298-2305
-
-
McDermott, D.F.1
-
27
-
-
40349103654
-
Angiotensin II induces oxidative stress in prostate cancer
-
Uemura H, Ishiguro H, Ishiguro Y, Hoshino K, Takahashi S, Kubota Y. Angiotensin II induces oxidative stress in prostate cancer. Mol Cancer Res 2008; 6: 250-8.
-
(2008)
Mol Cancer Res
, vol.6
, pp. 250-258
-
-
Uemura, H.1
Ishiguro, H.2
Ishiguro, Y.3
Hoshino, K.4
Takahashi, S.5
Kubota, Y.6
-
28
-
-
0347995046
-
Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis
-
Noguchi R, Yoshiji H, Kuriyama S et al. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 2003; 9: 6038-45.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 6038-6045
-
-
Noguchi, R.1
Yoshiji, H.2
Kuriyama, S.3
-
29
-
-
69049113864
-
Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy
-
Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 2009; 135: 1429-35.
-
(2009)
J Cancer Res Clin Oncol
, vol.135
, pp. 1429-1435
-
-
Wilop, S.1
von Hobe, S.2
Crysandt, M.3
Esser, A.4
Osieka, R.5
Jost, E.6
-
30
-
-
0030970053
-
Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine
-
Kinouchi T, Saiki S, Maeda O, Kuroda M, Usami M, Kotake T. Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine. J Urol 1997; 157: 1604-7.
-
(1997)
J Urol
, vol.157
, pp. 1604-1607
-
-
Kinouchi, T.1
Saiki, S.2
Maeda, O.3
Kuroda, M.4
Usami, M.5
Kotake, T.6
-
31
-
-
15444365932
-
Cancer, inflammation and the AT1 and AT2 receptors
-
Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond) 2004; 1: 3.
-
(2004)
J Inflamm (Lond)
, vol.1
, pp. 3
-
-
Smith, G.R.1
Missailidis, S.2
-
32
-
-
48749092867
-
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma
-
Melichar B, Koralewski P, Ravaud A et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-6.
-
(2008)
Ann Oncol
, vol.19
, pp. 1470-1476
-
-
Melichar, B.1
Koralewski, P.2
Ravaud, A.3
-
34
-
-
70249097380
-
Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
-
Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-8.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3312-3318
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
35
-
-
73349084973
-
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
-
Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5794-5799
-
-
Heng, D.Y.1
Xie, W.2
Regan, M.M.3
-
36
-
-
0037163481
-
Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study
-
Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002; 162: 1985-93.
-
(2002)
Arch Intern Med
, vol.162
, pp. 1985-1993
-
-
Clegg, L.X.1
Li, F.P.2
Hankey, B.F.3
Chu, K.4
Edwards, B.K.5
-
37
-
-
34548715340
-
Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004
-
Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK. Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004. Cancer 2007; 110: 1255-63.
-
(2007)
Cancer
, vol.110
, pp. 1255-1263
-
-
Robbins, A.S.1
Koppie, T.M.2
Gomez, S.L.3
Parikh-Patel, A.4
Mills, P.K.5
-
38
-
-
44149124558
-
Impact of gender in renal cell carcinoma: an analysis of the SEER database
-
Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 2008; 54: 133-40.
-
(2008)
Eur Urol
, vol.54
, pp. 133-140
-
-
Aron, M.1
Nguyen, M.M.2
Stein, R.J.3
Gill, I.S.4
-
39
-
-
72149129759
-
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients
-
Naito S, Yamamoto N, Takayama T et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010; 57: 317-25.
-
(2010)
Eur Urol
, vol.57
, pp. 317-325
-
-
Naito, S.1
Yamamoto, N.2
Takayama, T.3
-
40
-
-
4644324025
-
Cancer immunotherapy: moving beyond current vaccines
-
Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
-
(2004)
Nat Med
, vol.10
, pp. 909-915
-
-
Rosenberg, S.A.1
Yang, J.C.2
Restifo, N.P.3
-
41
-
-
77649330490
-
Learning from cancer: the adaptive growth, wound and immune responses
-
Smith GR, Missailidis S. Learning from cancer: the adaptive growth, wound and immune responses. Gene Ther Mol Biol 2009; 13: 158-85.
-
(2009)
Gene Ther Mol Biol
, vol.13
, pp. 158-185
-
-
Smith, G.R.1
Missailidis, S.2
-
42
-
-
34247628373
-
Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma
-
Recchia F, Saggio G, Amiconi G et al. Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma. J Immunother 2007; 30: 448-54.
-
(2007)
J Immunother
, vol.30
, pp. 448-454
-
-
Recchia, F.1
Saggio, G.2
Amiconi, G.3
-
43
-
-
33644832319
-
Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer
-
Recchia F, Saggio G, Nuzzo A et al. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer. J Immunother 2006; 29: 87-94.
-
(2006)
J Immunother
, vol.29
, pp. 87-94
-
-
Recchia, F.1
Saggio, G.2
Nuzzo, A.3
|